Brewster L L M, Kleijnen J, van Montfrans G A
Academic Medical Centre, Dept. of Internal Medicine F4-253, PO Box 22660, Amsterdam, Netherlands 1100 DD.
Cochrane Database Syst Rev. 2007 Jul 18;2005(1):CD005183. doi: 10.1002/14651858.CD005183.pub2.
Black people have a greater prevalence of elevated blood pressure leading to excess morbidity and mortality.
To systematically review the effects of different antihypertensive drugs on mortality, morbidity and blood pressure black adults with elevated blood pressure.
Medline, Embase, LILACS, African Index Medicus, the Cochrane Library November 2003; Pubmed September 2003 to March 2004. Searches were conducted without language restriction.
Randomised controlled trials of drugs versus placebo (blood pressure outcomes) or versus placebo or other drugs (morbidity and mortality outcomes).
Two reviewers independently extracted data unblinded. Disagreements were resolved by discussion. Authors were contacted twice to obtain missing information.
Full reports or abstracts from more than 2900 references of papers yielded 30 trials considering 53 interventions with 8 classes of antihypertensive drugs in 20,006 black patients from Africa, the Caribbean, and the United States of America, aged 18 to >80 years. In one large trial the main morbidity and mortality outcomes did not differ significantly between initial treatment drug classes when drugs were added to reach goal blood pressures. However, the comparison ACE Inhibitors vs diuretic favoured the diuretic for stroke 1.40 [1.17 to 1.68]; combined CHD 1.15 [1.02 to 1.30] and combined CVD 1.19 [1.09 to 1.30] and the comparison alpha blocker vs diuretic favoured the diuretic for combined CVD 1.40 [1.25 to 1.57]. In addition, all comparisons for heart failure favoured diuretic (1.47 [1.24 to 1.74] vs calcium blocker; 1.32 [1.11 to 1.58] vs ACE Inhibitor; and 2.18 [1.73 to 2.74] vs alpha blocker. The results also showed a greater occurrence of diabetes with diuretics. No significant differences were detected between placebo and beta adrenergic blockers in the reduction of systolic blood pressure (weighted mean difference [95% CI], -3.52 [-7.50 to 0.46] mm Hg). In addition, ACE inhibitors did not significantly differ from placebo in achievement of goal diastolic blood pressure (risk difference [95% CI], 5% [-10% to 21%]). Calcium blockers, diuretics, centrally acting agents, alpha adrenergic blockers and angiotensin II antagonists were all more effective than placebo in reducing blood pressure in the pooled analyses. Only calcium blockers remained effective in all prespecified subgroups, including baseline diastolic blood pressure >109 mm Hg.
AUTHORS' CONCLUSIONS: When first-line drugs from different classes are compared in the treatment of black people, there is no evidence of differential effects on most mortality and morbidity outcomes. Those morbidity differences that were found favoured diuretics. Drugs differ in their ability to reduce blood pressure in black people. Calcium blockers were the only drug class that reduced blood pressure in all subgroups of black people including those with severe hypertension. Beta-blockers, angiotensin receptor blocker, alpha blockers and ACE Inhibitors were least good at reducing blood pressure in black adults.
黑人高血压患病率更高,导致发病率和死亡率增加。
系统评价不同降压药物对血压升高的成年黑人死亡率、发病率和血压的影响。
检索了Medline、Embase、LILACS、非洲医学索引、2003年11月的Cochrane图书馆;2003年9月至2004年3月的Pubmed。检索无语言限制。
药物与安慰剂(血压结果)或与安慰剂或其他药物(发病率和死亡率结果)的随机对照试验。
两名评价员独立提取数据,未设盲。分歧通过讨论解决。两次联系作者以获取缺失信息。
从2900多篇参考文献的全文报告或摘要中筛选出30项试验,涉及来自非洲、加勒比地区和美国的20006名18至80岁以上的黑人患者,采用8类降压药物进行53种干预。在一项大型试验中,当添加药物以达到目标血压时,初始治疗药物类别之间的主要发病率和死亡率结果没有显著差异。然而,血管紧张素转换酶抑制剂与利尿剂的比较中,利尿剂在卒中方面更具优势,比值比为1.40[1.17至1.68];冠心病合并症为1.15[1.02至1.30],心血管疾病合并症为1.19[1.09至1.30];α受体阻滞剂与利尿剂的比较中,利尿剂在心血管疾病合并症方面更具优势,比值比为1.40[1.25至1.57]。此外,所有心力衰竭的比较中,利尿剂更具优势(与钙通道阻滞剂相比为1.47[1.24至1.74];与血管紧张素转换酶抑制剂相比为1.32[1.11至1.58];与α受体阻滞剂相比为2.18[1.73至2.74])。结果还显示,利尿剂导致糖尿病的发生率更高。安慰剂与β肾上腺素能阻滞剂在降低收缩压方面无显著差异(加权平均差[95%可信区间],-3.52[-7.50至0.46]mmHg)。此外,血管紧张素转换酶抑制剂与安慰剂在达到目标舒张压方面无显著差异(风险差[95%可信区间],5%[-10%至21%])。在汇总分析中,钙通道阻滞剂、利尿剂、中枢作用药物、α肾上腺素能阻滞剂和血管紧张素II拮抗剂在降低血压方面均比安慰剂更有效。只有钙通道阻滞剂在所有预先设定的亚组中均保持有效,包括基线舒张压>109mmHg的亚组。
在治疗黑人时比较不同类别的一线药物,没有证据表明对大多数死亡率和发病率结果有不同影响。发现的那些发病率差异有利于利尿剂。不同药物在降低黑人血压的能力上存在差异。钙通道阻滞剂是唯一能在包括重度高血压患者在内的所有黑人亚组中降低血压的药物类别。β受体阻滞剂、血管紧张素受体阻滞剂、α受体阻滞剂和血管紧张素转换酶抑制剂在降低成年黑人血压方面效果最差。